News

The FDA granted Wezlana with interchangeable designation after clinical trials found no clinically significant differences in safety and efficacy for the indicated conditions across multiple inflammatory diseases.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.

MarketsandMarkets report points to growth of over $3 billion over the next five years.

The latest people news happenings over the past month.

Effort displays the diverse perspectives, skills, and people involved with the healthcare supply chain, as industry aims to continue to push DE&I forward.

Surge acted as a precursor for the RSV-marketed drug landscape in 2023, says GlobalData.

Company to discuss acquisition and expansion of executive leadership.

New company to be publicly listed as Citius Oncology, Inc.

Parties will establish a Center of Excellence in CMIC’s NJ plant.

Investment offers opportunity to expand global footprint, company says.

DataHorizzon Research anticipates an 18.1% CAGR through next decade.

Thousands of pharmacies will earn streamlined access to the OneScan Pharmacy Pro Platform, company says.

Executive comes with over 20 years of experience in the industry.

Partnership intends to indirectly boost patient medication adherence rates in the process.

Sector is anticipated to grow at a CAGR of 9.3%.

Provider acquires Healthware Group, extending its international footprint.

Northern Ireland hub undergoes $85 million expansion.

Nazaré brings together KOLs who are knowledgeable of the pharma product lifecycle.

CDMO predicts that its facilities can now potentially produce over $400 million in annual revenue.

These components take the burden off drug manufacturers to prep packaging components for sterilization, while helping to enhance the drug filling and packaging process.

The Vicenza site will run about 54,000 square feet in size.

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.

CDMO’s goal is to increase building’s aseptic manufacturing capacity.

CDMO will financially commit $10.6 million toward semi-solid and non-sterile liquid production.

Deal includes Krazati, a therapy for patients with non-small cell lung cancer.

HDA research reveals that 95% of pharma transactions move through the traditional distribution channel.

CDMO’s Heidelberg facility will house the newly-completed manufacturing line.